Evidence map›Paper›PMID 42109027›Full record

ReviewAnnals of medicine2026

Harnessing

Yanfei Ji, Zhihao Wang, Yuxuan Feng, Irfan Ahmad, Khalid J Alzahrani, Khalaf F Alsharif, Fuad M Alzahrani, Xia Zhao, Abdul Qadeer, Wenqiang Liu

Abstract readReview
In one paragraph

Review in Annals of medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yanfei JiCollege of Agriculture and Biology, Liaocheng University, Liaocheng, China.
Zhihao WangCollege of Agriculture and Biology, Liaocheng University, Liaocheng, China.
Yuxuan FengNortheast Agricultural University College of Veterinary Medicine, Harbin, China.
Irfan AhmadDepartment of Clinical Laboratory Sciences, College of Applied Medical Sciences, King Khalid University, Abha, Saudi Arabia.
Khalid J AlzahraniDepartment of Clinical Laboratories Sciences, College of Applied Medical Sciences, Taif University, Taif, Saudi Arabia.
Khalaf F AlsharifDepartment of Clinical Laboratories Sciences, College of Applied Medical Sciences, Taif University, Taif, Saudi Arabia.
Fuad M AlzahraniDepartment of Clinical Laboratories Sciences, College of Applied Medical Sciences, Taif University, Taif, Saudi Arabia.
Xia ZhaoCollege of Agriculture and Biology, Liaocheng University, Liaocheng, China.
Abdul QadeerSchool of Medical Sciences, Shandong Xiehe University, Jinan, P. R. China.ORCID 0000-0002-0268-1167
Wenqiang LiuCollege of Agriculture and Biology, Liaocheng University, Liaocheng, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionDISCUSSION: Key MIC adhesin complexes - including the lectin-based MIC1/4/6 complex and the transmembrane MIC2-M2AP complex - mediate glycan recognition, host cell attachment, moving junction formation, and gliding motility. Beyond invasion, MICs function as immunomodulators engaging Toll-like receptors (TLR2, TLR4, TLR11) to elicit pro-inflammatory responses while activating EGFR-Akt signaling to inhibit autophagy. The translational potential is substantial: MIC-based antigens enable sensitive serodiagnosis, differentiating acute from chronic infections. In contrast, MIC-based vaccines across multiple platforms demonstrate considerable protective efficacy in preclinical experimental models. Notably, the MIC1-3 knockout strain confers protection in sheep that is comparable to that of commercial vaccines; however, it is important to note that most supporting evidence remains at the preclinical stage and clinical validation in human populations is still required.

conclusionsMICs represent promising targets that bridge fundamental parasitology and clinical applications. Integration of MIC biology with translational strategies provides foundations for developing next-generation diagnostics and vaccines against toxoplasmosis.

Indexed as

MicronemeProtozoan ProteinsProtozoan VaccinesToxoplasmaToxoplasmosisVaccine DevelopmentAnimalsAntigens, ProtozoanCell Adhesion MoleculesHost-Parasite InteractionsHumansSerologic TestsAntigens, ProtozoanCell Adhesion MoleculesMIC1 protein, Toxoplasma gondiiProtozoan ProteinsProtozoan Vaccineshost cell invasionimmunomodulationmicroneme proteinsserodiagnosisToxoplasma gondiivaccine development

Identifiers

PMID42109027
PMCPMC13162539

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.